Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00720564 · ClinicalTrials.gov registry record · Phase 1
Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00720564 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 18 participants.
The verdict
NCT00720564, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as arsenic trioxide and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Arsenic trioxide and temozolomide may also make tumor cells more sensitive to radiation therapy. Giving radiation therapy together with combination chemotherapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of arsenic trioxide when given together with temozolomide and radiation therapy in treating patients with newly diagnosed high-grade glioma.
Interventions
- DRUG temozolomide
- RADIATION intensity-modulated radiation therapy
- RADIATION radiation therapy
- PROCEDURE adjuvant therapy
- DRUG arsenic trioxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00720564
The ClinicalTrials.gov registry entry for NCT00720564 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which temozolomide is the first listed.
NCT00720564 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00720564 about?
NCT00720564 is a clinical study titled "Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma". RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as arsenic trioxide and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Arsenic trioxide and temozolomide ...
What is the current status of trial NCT00720564?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2008-04. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00720564?
The interventions under investigation include: temozolomide (DRUG), intensity-modulated radiation therapy (RADIATION), radiation therapy (RADIATION), adjuvant therapy (PROCEDURE), arsenic trioxide (DRUG).
Who is sponsoring clinical trial NCT00720564?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.